A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.

@article{Hammer1996ATC,
  title={A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.},
  author={Scott M. Hammer and David K. Katzenstein and Michael R. Hughes and Holly M Gundacker and Robert Turner Schooley and Richard Haubrich and William Keith Henry and Michael M. Lederman and John P. Phair and Meijuan Niu and Martin S. Hirsch and Thomas C. Merigan},
  journal={The New England journal of medicine},
  year={1996},
  volume={335 15},
  pages={1081-90}
}
BACKGROUND This double-blind study evaluated treatment with either a single nucleoside or two nucleosides in adults infected with human immunodeficiency virus type 1 (HIV-1) whose CD4 cell counts were from 200 to 500 per cubic millimeter. METHODS We randomly assigned 2467 HIV-1--infected patients (43 percent without prior antiretroviral treatment) to one of four daily regimens: 600 mg of zidovudine; 600 mg of zidovudine plus 400 mg of didanosine; 600 mg of zidovudine plus 2.25 mg of… CONTINUE READING